よむ、つかう、まなぶ。
07 参考資料２－１ 帯状疱疹ワクチン ファクトシート (49 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36248.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第21回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
83. Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam
SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW. Safety and
immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J
Infect Dis 2013; 208: 1375-85.
84. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin
MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf
T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit
vaccine in older adults. N Engl J Med 2015; 372: 2087-96.
85. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux
O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe
D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey
HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo
L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the
herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:
1019-32.
86. 外山望. 地域皮膚科医コミュニティの連携が生んだ大規模帯状疱疹疫学調査報告
（宮崎スタディ）75,789 例（1997 年～2011 年）. 日本臨床皮膚科医会雑誌 2012; 29:
799-804.
87. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the
epidemiology of herpes zoster in Korea.Population-based study of the epidemiology of
herpes zoster in Korea. J Korean Med Sci. 2014; 29: 1706-10.
88. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo
R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic
neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10:
230.
89. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates
of herpes zoster among an immunocompetent population in the United States. BMC Infect
Dis 2015; 15: 502.
90. Morant-Talamante
N, Diez-Domingo
J, Martínez-Úbeda
S, Puig-Barberá
J, Alemán-Sánchez S, Pérez-Breva L. Herpes zoster surveillance using electronic databases
in the Valencian Community (Spain). BMC Infect Dis 2013; 13: 463.
91. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in
Germany: quantifying the burden of disease. BMC Infect Dis 2011; 11: 173.
92. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow
O, Blanchon T, Hanslik T. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:
7933-8.
44
SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW. Safety and
immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J
Infect Dis 2013; 208: 1375-85.
84. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin
MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf
T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit
vaccine in older adults. N Engl J Med 2015; 372: 2087-96.
85. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux
O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe
D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey
HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo
L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the
herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:
1019-32.
86. 外山望. 地域皮膚科医コミュニティの連携が生んだ大規模帯状疱疹疫学調査報告
（宮崎スタディ）75,789 例（1997 年～2011 年）. 日本臨床皮膚科医会雑誌 2012; 29:
799-804.
87. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the
epidemiology of herpes zoster in Korea.Population-based study of the epidemiology of
herpes zoster in Korea. J Korean Med Sci. 2014; 29: 1706-10.
88. Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo
R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic
neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10:
230.
89. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates
of herpes zoster among an immunocompetent population in the United States. BMC Infect
Dis 2015; 15: 502.
90. Morant-Talamante
N, Diez-Domingo
J, Martínez-Úbeda
S, Puig-Barberá
J, Alemán-Sánchez S, Pérez-Breva L. Herpes zoster surveillance using electronic databases
in the Valencian Community (Spain). BMC Infect Dis 2013; 13: 463.
91. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in
Germany: quantifying the burden of disease. BMC Infect Dis 2011; 11: 173.
92. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow
O, Blanchon T, Hanslik T. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:
7933-8.
44